comparemela.com

Latest Breaking News On - Epontis - Page 2 : comparemela.com

EQS-Adhoc: APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 - adhoc - Börsennachrichten

EQSAdhoc APONTIS PHARMA AG Key word Change in ForecastProfit Warning APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and mediumterm planning for 2026 27Jul2023 2210 CETCEST Disclosure of an

Sven paulyKarlheinz gastSingle pill

Corporate volunteers will help across Slovakia on Friday

The Slovak National Gallery will take part in the Naše Mesto corporate volunteering event for the first time on Friday.

Slovak republicNew yorkUnited statesPre ovskýDavid kolSlovak national galleryPontis foundationHave my heartAse mesto

APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights

EQS-News: APONTIS PHARMA AG / Key word: Product Launch APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for. | May 8, 2023

Czech republicSven paulyKarlheinz gastMartin albertZentiva groupSingle pillSingle pillsChief executive officerChief scientific officerApontis pharma ag stock exchangePress releaseRoup apph de000a3cmgm5

APONTIS PHARMA AG adjusts forecast for fiscal year 2023

EQS-Ad-hoc: APONTIS PHARMA AG / Key word: Forecast/Change in Forecast APONTIS PHARMA AG adjusts forecast for fiscal year 2023 02-May-2023 / 21:50 CET/CEST Disclosure of an inside information. | May 2, 2023

Sven paulyGerman federal institute for drugsSingle pillsGerman federal instituteMedical devicesSingle pillApontis pharma ag stock exchangePress releaseNside apph de000a3cmgm5

APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential

EQS-News: APONTIS PHARMA AG / Key word: Product Launch APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property. | April 12, 2023

Rheinland pfalzKarlheinz gastKarl heinz schleicherSven paulyManufacturing organisationContract developmentMidas pharma groupMidas pharmaSingle pillSingle pillsChief executive officerHeinz schleicherStarting materialsActive pharmaceutical ingredientsFinished productsPharma group

vimarsana © 2020. All Rights Reserved.